# Long-term Safety of Danicopan: IPIG Registry-based Cohort Study

> **NCT07413679** · — · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria
- PNH

## Interventions

- **DRUG:** Danicopan

## Key facts

- **NCT ID:** NCT07413679
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2029-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07413679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07413679, "Long-term Safety of Danicopan: IPIG Registry-based Cohort Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07413679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*